PARD.US Poniard Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 15, 2026
Market cap
USD 149.00
P/E
-
P/B
0.10x
ROE
-465.2%
Dividend yield
128,859.06%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2011.

Is PARD.US undervalued?

Graham number

The Graham number of Poniard Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Poniard Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Poniard Pharmaceuticals Inc yet.

Poniard Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Poniard Pharmaceuticals Inc

Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase I…

Full company profile